XEN1101 in Focal Epilepsy

Market
100%75%50%25%0%Apr 20 • YES 90.0%Apr 20
Trade

Will this trial meet its primary endpoint?

Paper Trading
Create account to trade
DetailsModel PositionsModel SnapshotsOracle
Primary Completion
9/2/21
Study Completion
10/1/28
Sponsor
Xenon Pharmaceuticals Inc.
$XENE
Type
Phase 2
Trial Status
Active, not recruiting
Trial Size
325
Volume
$0
NCT
NCT03796962
Trial Description
This Phase 2 randomized, double-blind, placebo-controlled multicenter study evaluates oral XEN1101 as adjunctive therapy in adults with focal-onset epilepsy, with an optional open-label extension. Posted results show larger median reductions in focal seizure frequency for XEN1101 dose groups, particularly 25 mg and 20 mg, versus placebo during the double-blind period, while the record remains active because the extension is ongoing.